Acumen regains rights to Alzheimer's programme from Merck & Co
This article was originally published in Scrip
Executive Summary
Merck & Co has terminated a 2003 agreement with Acumen Pharmaceuticals and returned rights to develop and commercialise its anti-amyloid-derived diffusible ligand (ADDL) antibody therapeutics and diagnostics for Alzheimer's disease.